Biopharmaceutics Data Management System for Anonymised Data Sharing and Curation: First Application with OrBiTo IMI Project

Over the last decade, drug development cost has increased exponentially [1], which led to the pharmaceutical industry together with academia and drug regulatory agencies, increasing efforts on “pre-competitive” research collaborations in various areas [2-4]. This research involves some lever of data sharing, but the disclosure of novel therapeutically active molecules’ attributes in an open database is in direct opposition to what gives the competitive advantages to the innovator de veloper. Some of the difficulties associated with full information disclosure are previously highlighted in other journal articles [5].

Source: Computer Methods and Programs in Biomedicine - November 17, 2016 Category: Bioinformatics Authors: Kristin Lacy-Jones, Philip Hayward, Steve Andrews, Ian Gledhill, Mark McAllister, Bertil Abrahamsson, Amin Rostami-Hodjegan, Xavier Pepin Source Type: research